Enhanced vitamin K (Menaquinone-7) production by Bacillus subtilis natto in biofilm reactors by optimization of glucose-based medium

Ehsan Mahdinia, Ali Demirci, Aydin Berenjian

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Benefits of vitamin K have been reported by many studies recently, due to its ability to reduce the risk of cardiovascular diseases and its potential benefits against osteoporosis. Specifically, menaquinone-7 (MK-7), being the most potent form of vitamin K, has definitely received most of the attention. Currently, solid or static liquid fermentation strategies are utilized for industrial production of MK-7 by Bacillus strains. However, these strategies face fundamental operational and scale-up issues as well as intense pellicle and biofilm formations which is problematic in static liquid fermentation, due to heat and mass transfer inefficiencies they create. Objective: The purpose of this study was to demonstrate that biofilm reactors will overcome the issues associated with suspended cell reactors when using Bacillus strains to produce MK-7. The expectation is that the use of biofilm reactors will result in a significant increase in the production of MK-7. Method: Vitamin K production by Bacillus subtilis natto when grown in a biofilm reactor was evaluated at various concentrations of the three major nutrients, glucose, yeast extract and casein. The data was analyzed using response surface methodology (RSM). Results: The maximum concentration of MK-7 in the biofilm reactors was 20.5±0.5 mg/L, which was a 344 % increase when compared to the amount produced in suspended-cell reactors containing the same optimum media composition. Conclusion: These results demonstrate the potential of utilizing biofilm reactors for MK-7 production on an industrial scale.

Original languageEnglish (US)
Pages (from-to)917-924
Number of pages8
JournalCurrent Pharmaceutical Biotechnology
Volume19
Issue number11
DOIs
StatePublished - Jan 1 2019

Fingerprint

Vitamin K
Biofilms
Bacillus subtilis
Glucose
Bacillus
Fermentation
Caseins
Osteoporosis
vitamin MK 7
Cardiovascular Diseases
Hot Temperature
Yeasts
Food

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Pharmaceutical Science

Cite this

@article{3782e22745d947b8bb3ef75518e39f8c,
title = "Enhanced vitamin K (Menaquinone-7) production by Bacillus subtilis natto in biofilm reactors by optimization of glucose-based medium",
abstract = "Background: Benefits of vitamin K have been reported by many studies recently, due to its ability to reduce the risk of cardiovascular diseases and its potential benefits against osteoporosis. Specifically, menaquinone-7 (MK-7), being the most potent form of vitamin K, has definitely received most of the attention. Currently, solid or static liquid fermentation strategies are utilized for industrial production of MK-7 by Bacillus strains. However, these strategies face fundamental operational and scale-up issues as well as intense pellicle and biofilm formations which is problematic in static liquid fermentation, due to heat and mass transfer inefficiencies they create. Objective: The purpose of this study was to demonstrate that biofilm reactors will overcome the issues associated with suspended cell reactors when using Bacillus strains to produce MK-7. The expectation is that the use of biofilm reactors will result in a significant increase in the production of MK-7. Method: Vitamin K production by Bacillus subtilis natto when grown in a biofilm reactor was evaluated at various concentrations of the three major nutrients, glucose, yeast extract and casein. The data was analyzed using response surface methodology (RSM). Results: The maximum concentration of MK-7 in the biofilm reactors was 20.5±0.5 mg/L, which was a 344 {\%} increase when compared to the amount produced in suspended-cell reactors containing the same optimum media composition. Conclusion: These results demonstrate the potential of utilizing biofilm reactors for MK-7 production on an industrial scale.",
author = "Ehsan Mahdinia and Ali Demirci and Aydin Berenjian",
year = "2019",
month = "1",
day = "1",
doi = "10.2174/1389201020666181126120401",
language = "English (US)",
volume = "19",
pages = "917--924",
journal = "Current Pharmaceutical Biotechnology",
issn = "1389-2010",
publisher = "Bentham Science Publishers B.V.",
number = "11",

}

Enhanced vitamin K (Menaquinone-7) production by Bacillus subtilis natto in biofilm reactors by optimization of glucose-based medium. / Mahdinia, Ehsan; Demirci, Ali; Berenjian, Aydin.

In: Current Pharmaceutical Biotechnology, Vol. 19, No. 11, 01.01.2019, p. 917-924.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Enhanced vitamin K (Menaquinone-7) production by Bacillus subtilis natto in biofilm reactors by optimization of glucose-based medium

AU - Mahdinia, Ehsan

AU - Demirci, Ali

AU - Berenjian, Aydin

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Benefits of vitamin K have been reported by many studies recently, due to its ability to reduce the risk of cardiovascular diseases and its potential benefits against osteoporosis. Specifically, menaquinone-7 (MK-7), being the most potent form of vitamin K, has definitely received most of the attention. Currently, solid or static liquid fermentation strategies are utilized for industrial production of MK-7 by Bacillus strains. However, these strategies face fundamental operational and scale-up issues as well as intense pellicle and biofilm formations which is problematic in static liquid fermentation, due to heat and mass transfer inefficiencies they create. Objective: The purpose of this study was to demonstrate that biofilm reactors will overcome the issues associated with suspended cell reactors when using Bacillus strains to produce MK-7. The expectation is that the use of biofilm reactors will result in a significant increase in the production of MK-7. Method: Vitamin K production by Bacillus subtilis natto when grown in a biofilm reactor was evaluated at various concentrations of the three major nutrients, glucose, yeast extract and casein. The data was analyzed using response surface methodology (RSM). Results: The maximum concentration of MK-7 in the biofilm reactors was 20.5±0.5 mg/L, which was a 344 % increase when compared to the amount produced in suspended-cell reactors containing the same optimum media composition. Conclusion: These results demonstrate the potential of utilizing biofilm reactors for MK-7 production on an industrial scale.

AB - Background: Benefits of vitamin K have been reported by many studies recently, due to its ability to reduce the risk of cardiovascular diseases and its potential benefits against osteoporosis. Specifically, menaquinone-7 (MK-7), being the most potent form of vitamin K, has definitely received most of the attention. Currently, solid or static liquid fermentation strategies are utilized for industrial production of MK-7 by Bacillus strains. However, these strategies face fundamental operational and scale-up issues as well as intense pellicle and biofilm formations which is problematic in static liquid fermentation, due to heat and mass transfer inefficiencies they create. Objective: The purpose of this study was to demonstrate that biofilm reactors will overcome the issues associated with suspended cell reactors when using Bacillus strains to produce MK-7. The expectation is that the use of biofilm reactors will result in a significant increase in the production of MK-7. Method: Vitamin K production by Bacillus subtilis natto when grown in a biofilm reactor was evaluated at various concentrations of the three major nutrients, glucose, yeast extract and casein. The data was analyzed using response surface methodology (RSM). Results: The maximum concentration of MK-7 in the biofilm reactors was 20.5±0.5 mg/L, which was a 344 % increase when compared to the amount produced in suspended-cell reactors containing the same optimum media composition. Conclusion: These results demonstrate the potential of utilizing biofilm reactors for MK-7 production on an industrial scale.

UR - http://www.scopus.com/inward/record.url?scp=85057496980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057496980&partnerID=8YFLogxK

U2 - 10.2174/1389201020666181126120401

DO - 10.2174/1389201020666181126120401

M3 - Article

C2 - 30474527

AN - SCOPUS:85057496980

VL - 19

SP - 917

EP - 924

JO - Current Pharmaceutical Biotechnology

JF - Current Pharmaceutical Biotechnology

SN - 1389-2010

IS - 11

ER -